CCRCC
MCID: CLR030
MIFTS: 49

Clear Cell Renal Cell Carcinoma (CCRCC)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 54 60 15
Clear-Cell Metastatic Renal Cell Carcinoma 12 54 74
Clear Cell Carcinoma of Kidney 12 30 6
Conventional Renal Cell Carcinoma 12 74
Renal Clear Cell Carcinoma 12 56
Clear Cell Renal Carcinoma 60 17
Clear Cell Renal Cell Adenocarcinoma 60
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 54
Clear Cell Rcc 54
Ccrcc 60

Classifications:

Orphanet: 60  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 45 D002292
NCIt 51 C4033
SNOMED-CT 69 41607009
ICD10 via Orphanet 35 C64
UMLS via Orphanet 75 C0279702
Orphanet 60 ORPHA319276

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 54 Clear cell renal cell carcinoma is a cancer of the kidney.  The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.  Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1). The drugs Aldesleukin and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 33.5 CYTOR HNF1A LINC00887 MALAT1 OGG1 PANDAR
2 clear cell papillary renal cell carcinoma 31.1 HNF1A PBRM1
3 kidney cancer 30.8 MALAT1 MEG3 PVT1
4 intrahepatic cholangiocarcinoma 30.5 CCAT2 PBRM1 TUG1
5 myeloma, multiple 30.4 MALAT1 MEG3 PVT1 TUG1
6 thyroid cancer, nonmedullary, 1 30.4 MALAT1 MEG3 PVT1
7 cholangiocarcinoma 30.2 CCAT2 MALAT1 OGG1 PANDAR SPRY4-IT1 TUG1
8 esophageal cancer 30.1 CYTOR LUCAT1 MALAT1 MEG3 PVT1
9 melanoma 30.0 MALAT1 MEG3 PVT1 SPRY4-IT1
10 diabetes mellitus 29.8 HNF1A MALAT1 MEG3 PVT1 TUG1
11 breast cancer 29.5 CCAT2 CYTOR MALAT1 MEG3 NBAT1 PANDAR
12 lung cancer 29.5 ADAMTS9-AS2 CCAT2 DGCR5 LUCAT1 MALAT1 MEG3
13 multilocular clear cell renal cell carcinoma 12.6
14 hereditary conventional renal cell carcinoma 12.4
15 multilocular cystic renal neoplasm of low malignant potential 11.7
16 chromophobe renal cell carcinoma 11.6
17 birt-hogg-dube syndrome 11.2
18 von hippel-lindau syndrome 11.2
19 renal cell carcinoma, xp11-associated 11.2
20 hypoxia 10.7
21 angiomyolipoma 10.5
22 renal cell carcinoma, papillary, 1 10.4
23 oncocytoma 10.4
24 hemangioblastoma 10.4
25 ovarian epithelial cancer 10.4 MALAT1 MEG3
26 microvascular complications of diabetes 3 10.4 MALAT1 PVT1
27 pituitary adenoma 10.3 CCAT2 MALAT1 MEG3
28 malignant glioma 10.3 CYTOR PVT1 SPRY4-IT1 TUG1
29 vulva squamous cell carcinoma 10.3 MALAT1 MEG3
30 squamous cell carcinoma 10.3 CCAT2 MALAT1 SPRY4-IT1 TUG1
31 tongue squamous cell carcinoma 10.3 CYTOR MALAT1 MEG3
32 small cell cancer of the lung 10.3 CCAT2 MALAT1 TUG1
33 testicular germ cell cancer 10.3 MEG3 SPRY4-IT1
34 adenocarcinoma 10.2
35 oral squamous cell carcinoma 10.2 CCAT2 MALAT1 MEG3 TUG1
36 bladder urothelial carcinoma 10.2 MALAT1 MEG3 PVT1 TUG1
37 gallbladder cancer 10.2 CYTOR MALAT1 MEG3 TUG1
38 lung squamous cell carcinoma 10.2 CCAT2 MEG3 PVT1 TUG1
39 insulin-like growth factor i 10.2
40 body mass index quantitative trait locus 1 10.2
41 renal oncocytoma 10.2
42 chromophil renal cell carcinoma 10.2
43 b-cell lymphomas 10.2 MALAT1 PVT1 TUG1
44 glioma 10.1 CCAT2 CYTOR LUCAT1 MALAT1 MEG3 PVT1
45 hemangioma 10.1
46 hepatitis 10.1
47 hepatitis a 10.1
48 adenoma 10.1
49 osteogenic sarcoma 10.1 CCAT2 LUCAT1 MALAT1 MEG3 PANDAR PVT1
50 pancreatic cancer 10.0 CYTOR MALAT1 MEG3 PVT1 SPRY4-IT1 TUG1

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
2
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
4
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
5
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 946414-94-4
6 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
9 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
16 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
18
Iodine Approved, Investigational Phase 3 7553-56-2 807
19
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
20
Everolimus Approved Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177 70789204
21
Sirolimus Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
23
Axitinib Approved, Investigational Phase 3,Phase 2,Phase 1 319460-85-0 6450551
24 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
25 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Micronutrients Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents, Local Phase 3
29 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 cadexomer iodine Phase 3
32 Nutrients Phase 3,Phase 2,Phase 1
33 Trace Elements Phase 3,Phase 2,Phase 1
34 Interferon alpha-2 Phase 3,Phase 2,Phase 1
35 interferons Phase 3,Phase 2,Phase 1
36 Interferon-alpha Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2,Not Applicable
38 Antifungal Agents Phase 3,Phase 1,Phase 2,Not Applicable
39 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
40 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
41 tyrosine Phase 3,Phase 1,Phase 2
42 Immunoglobulin G Phase 3,Phase 2,Phase 1,Early Phase 1
43 Endothelial Growth Factors Phase 3,Phase 2,Phase 1,Early Phase 1
44 Mitogens Phase 3,Phase 2,Phase 1,Early Phase 1
45 Immunoconjugates Phase 3,Phase 1
46
Dalteparin Approved Phase 1, Phase 2 9005-49-6
47
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 46507594
48
Tinzaparin Approved Phase 1, Phase 2 9041-08-1, 9005-49-6 25244225
49
Panobinostat Approved, Investigational Phase 2,Phase 1 404950-80-7 6918837
50
Levoleucovorin Approved, Investigational Phase 2 68538-85-2

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
3 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
5 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
6 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Unknown status NCT01099423 Phase 3
7 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
8 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
9 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
10 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
11 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
12 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
13 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
14 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
15 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
16 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
17 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study Not yet recruiting NCT03849118 Phase 3
18 Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Not yet recruiting NCT03793166 Phase 3 Cabozantinib
19 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated NCT01599754 Phase 3 Axitinib;Placebo
20 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Terminated NCT01198158 Phase 3 Everolimus
21 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Terminated NCT02535351 Phase 3 sunitinib or pazopanib
22 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
23 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
24 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
25 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
26 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
27 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
28 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
29 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
30 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
31 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
32 Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Completed NCT02923531 Phase 1, Phase 2 X4P-001;Nivolumab
33 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
34 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
35 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
36 Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
37 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Completed NCT00408902 Phase 2 tandutinib
38 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
39 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
40 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Completed NCT00323739 Phase 2 bevacizumab;RAD001
41 Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus Completed NCT01715935 Phase 2 Everolimus
42 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
43 Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer Completed NCT00278174 Phase 2
44 Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Completed NCT00392821 Phase 1, Phase 2 Sorafenib;RAD001
45 Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01158222 Phase 2 sunitinib malate
46 Rotating Pazopanib and Everolimus to Avoid Resistance Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
47 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
48 Bryostatin 1 In Treating Patients With Progressive Kidney Cancer Completed NCT00005056 Phase 2 bryostatin 1
49 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
50 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy Completed NCT01141569 Phase 2 Gamma-Secretase Inhibitor RO4929097

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 30

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

42
Kidney, Endothelial, T Cells, Bone, Lung, Brain, Neutrophil

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 1818)
# Title Authors Year
1
Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status. ( 30601030 )
2019
2
Soyasapogenol B exhibits anti-growth and anti-metastatic activities in clear cell renal cell carcinoma. ( 30607469 )
2019
3
New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. ( 30616081 )
2019
4
Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma. ( 30617181 )
2019
5
Aggressive TFEB-rearranged renal cell carcinoma mimicking chromophobe and clear cell renal cell carcinoma. ( 30620430 )
2019
6
Predictive models composed by radiomic features extracted from multi-detector computed tomography images for predicting low- and high- grade clear cell renal cell carcinoma: A STARD-compliant article. ( 30633175 )
2019
7
Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma. ( 30637356 )
2019
8
DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma. ( 30642274 )
2019
9
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. ( 30645700 )
2019
10
N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis. ( 30648791 )
2019
11
Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma Are Prognostic for Outcome after Complete Metastasectomy. ( 30652998 )
2019
12
GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. ( 30653515 )
2019
13
Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. ( 30655088 )
2019
14
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. ( 30660076 )
2019
15
RAB27A is an independent prognostic factor in clear cell renal cell carcinoma. ( 30661368 )
2019
16
MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. ( 30668544 )
2019
17
Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway. ( 30670025 )
2019
18
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. ( 30670497 )
2019
19
Collision Tumor of Urothelial Cell Carcinoma and Clear Cell Renal Cell Carcinoma: A Case Report and Review of the Contemporary Literature. ( 30672774 )
2019
20
Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. ( 30680212 )
2019
21
Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma. ( 30680959 )
2019
22
Metastases to the nose from clear cell renal cell carcinoma: A case report. ( 30681558 )
2019
23
Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. ( 30683903 )
2019
24
Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis. ( 30697081 )
2019
25
Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma. ( 30701441 )
2019
26
SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis. ( 30703481 )
2019
27
The prognostic value of the site of invasion in T3aN0M0 clear cell renal cell carcinoma. ( 30704960 )
2019
28
[Corrigendum] miR‑122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3. ( 30720052 )
2019
29
Fructose 1,6-Bisphosphatase 1 Expression Reduces 18F-FDG Uptake in Clear Cell Renal Cell Carcinoma. ( 30723389 )
2019
30
The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients. ( 30723706 )
2019
31
Rare abdominal cutaneous presentation of clear cell renal cell carcinoma: a case report. ( 30738883 )
2019
32
Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma. ( 30758643 )
2019
33
Preoperative controlling nutritional status (CONUT) score as a novel immune-nutritional predictor of survival in non-metastatic clear cell renal cell carcinoma of ≤ 7 cm on preoperative imaging. ( 30758671 )
2019
34
Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation. ( 30760414 )
2019
35
Accumulation of fructose 1,6-bisphosphate protects clear cell renal cell carcinoma from oxidative stress. ( 30760861 )
2019
36
TOX3 Inhibits Cancer Cell Migration and Invasion via Transcriptional Regulation of SNAI1 and SNAI2 in Clear Cell Renal Cell Carcinoma. ( 30772441 )
2019
37
Low Expression of ATM Indicates a Poor Prognosis in Clear Cell Renal Cell Carcinoma. ( 30773312 )
2019
38
Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma. ( 30777326 )
2019
39
Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT. ( 30778739 )
2019
40
Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. ( 30784023 )
2019
41
The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. ( 30792476 )
2019
42
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. ( 30799404 )
2019
43
The Nrf2/HO-1 axis can be a prognostic factor in clear cell renal cell carcinoma. ( 30799949 )
2019
44
Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma. ( 30799953 )
2019
45
KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation. ( 30805928 )
2019
46
Overexpression of BHLHE41, correlated with DNA hypomethylation in 3'UTR region, promotes the growth of human clear cell renal cell carcinoma. ( 30816499 )
2019
47
Images - pT3a clear-cell renal cell carcinoma in a renal allograft managed effectively with open partial nephrectomy. ( 30817283 )
2019
48
High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma. ( 30819726 )
2019
49
IDUA, NDST1, SAP30L, CRYBA4, and SI as novel prognostic signatures clear cell renal cell carcinoma. ( 30820959 )
2019
50
The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals. ( 30824757 )
2019

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387
2 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh38 Chromosome 3, 52563364: 52563371
3 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
4 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh38 Chromosome 3, 9750423: 9750423
5 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
6 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh38 Chromosome 12, 120994322: 120994322
7 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Uncertain significance rs137853247 GRCh37 Chromosome 12, 121416663: 121416663
8 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Uncertain significance rs137853247 GRCh38 Chromosome 12, 120978860: 120978860

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 2154)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 0
2 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 0
3 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 0
4 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 0
5 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 0
6 COSM6970086 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 0
7 COSM3276983 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 0
8 COSM6961023 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 0
9 COSM6935891 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 0
10 COSM6946890 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 0
11 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 0
12 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 0
13 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 11:32434810-32434810 0
14 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 11:32391971-32391971 0
15 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 0
16 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 0
17 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 0
18 COSM6930635 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 0
19 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 8:99274262-99274262 0
20 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 3:10149822-10149822 0
21 COSM18074 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.193T>C p.S65P 3:10142040-10142040 0
22 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 0
23 COSM30224 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>G p.I109S 3:10142173-10142173 0
24 COSM17715 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.221T>A p.V74D 3:10142068-10142068 0
25 COSM17855 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.233A>G p.N78S 3:10142080-10142080 0
26 COSM18152 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>A p.V155M 3:10146636-10146636 0
27 COSM14375 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 0
28 COSM18024 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.598C>T p.R200W 3:10149921-10149921 0
29 COSM18350 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 0
30 COSM14368 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.473T>A p.L158Q 3:10149796-10149796 0
31 COSM14390 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.269A>T p.N90I 3:10142116-10142116 0
32 COSM249129 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.163G>T p.E55* 3:10142010-10142010 0
33 COSM1731995 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.328C>A p.H110N 3:10142175-10142175 0
34 COSM18069 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.407T>A p.F136Y 3:10146580-10146580 0
35 COSM6918107 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.302T>G p.L101R 3:10142149-10142149 0
36 COSM25682 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.430G>T p.G144* 3:10146603-10146603 0
37 COSM3364888 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.221T>G p.V74G 3:10142068-10142068 0
38 COSM18192 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.350G>T p.W117L 3:10146523-10146523 0
39 COSM97092 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>A p.P81T 3:10142088-10142088 0
40 COSM14363 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.458T>C p.L153P 3:10146631-10146631 0
41 COSM34005 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>G p.S65W 3:10142041-10142041 0
42 COSM249280 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.264G>A p.W88* 3:10142111-10142111 0
43 COSM17612 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.481C>T p.R161* 3:10149804-10149804 0
44 COSM17875 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.234T>G p.N78K 3:10142081-10142081 0
45 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 3:10146561-10146561 0
46 COSM17854 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.551T>C p.L184P 3:10149874-10149874 0
47 COSM18346 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341G>C p.G114A 3:10146514-10146514 0
48 COSM33993 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.404T>A p.L135* 3:10146577-10146577 0
49 COSM18415 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.263G>C p.W88S 3:10142110-10142110 0
50 COSM14328 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.351G>T p.W117C 3:10146524-10146524 0

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....